Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion

Malignant pleural mesothelioma (MPM) is a rare and deadly malignancy with an extremely poor prognosis. The median overall survival (OS) of this disease is 12–18 months. However, the oncogenic driver mutations of MPM are rarely understood, and the targeted therapy for it is still under investigation....

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xuehua, You, Mengxing, Meng, Erhong, Wang, Shunyou, Niu, Beifang, Huang, Weiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Letter to the Editors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349100/
https://www.ncbi.nlm.nih.gov/pubmed/35648195
http://dx.doi.org/10.1007/s00432-022-04076-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349100/
https://www.ncbi.nlm.nih.gov/pubmed/35648195
http://dx.doi.org/10.1007/s00432-022-04076-0

Ejemplares similares